Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists

Abstract

Aprepitant allows for better control of CINV in HEC regimens with CDDP, and this control is accurately perceived by physicians and nurses. However, physicians and nurses overestimate the control of delayed CINV after HEC regimens without CDDP and after MEC. CINV is still an important target for improved therapeutic intervention and the healthcare providers must be aware of its actual incidence.

Impact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life in Indonesian Patients With Gynecologic Cancer

“…4 Health professionals often underestimate the incidence and prevalence of CINV. 5 Most gynecologic cancer types are treated with highly emetogenic chemotherapeutics, such as cisplatin, carboplatin, paclitaxel, and cyclophosphamide when paclitaxel is not available. 6 These drugs are reported to cause emesis in more than 90% of patients without prophylactic use of antiemetics 7 and may seriously impact QoL.…”

Evaluation of the validity of chemotherapy-induced nausea and vomiting assessment in outpatients using the Japanese version of the MASCC antiemesis tool

“…Since healthcare professionals tend to underestimate symptoms compared with patients [17,18], methods based on patient reports are more appropriate to accurately record the symptoms. Many tools based on patient reports have been shown to be effective in recording CINV symptoms, including the Morrow assessment of nausea and emesis (MANE) [24], Rhodes INRV [21], Osoba Nausea and Emesis Module based on the European Organization for Research and Treatment of Cancer (EORTE) QLQ-C30 [25], CINE QOL questionnaire by Martin et al [26], and Functional Living Index-Emesis (FLIE) with a focus on QOL [27].…”

“…In clinical settings, however, a daily patient diary is seldom used because of the burden on the patients who fill it in and the healthcare professionals who analyze and assess the results. In outpatients receiving cancer chemotherapy in particular, physicians often assess symptoms observed during consultations alone, generating a gap between symptoms assessed by healthcare professionals and those really experienced by patients [17,18], and thus precluding appropriate treatment.…”

Controlling Chemotherapy-Induced Nausea and Vomiting with Neurokinin-1 Receptor Antagonists in Patients on AC-Based Chemotherapy—Are We There Yet?

“…The recent re-classification of the AC regimen from being moderately-emetogenic to highly-emetogenic by the American Society of Clinical Oncology [34] suggests the need to improve the use of NK1-RAs, such as aprepitant, in CINV control. Furthermore, it was found that clinicians tend to underestimate the incidences of nausea [34], as well as overestimate the control of delayed CINV in patients on MECs and HECs without cisplatin [35]. As such, there is also imperative need for more research to be done in this area.…”